Land of Opportunity
Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.
Stephanie Sutton |
Since its founding in 2015, the Biosimilars Council – a division of the Association for Accessible Medicines – has worked to ensure a positive, reimbursement, political and policy environment for biosimilar products, and educate the public and patients about the safety and effectiveness of biosimilars. We spoke with Craig Burton, Vice President of Policy at the Association for Accessible Medicines to learn more about the thorny path for biosimilars in the US.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.